This is a phase 4, multicenter, randomized, non-therapeutic interventional trial in subjects with psoriasis looking for the prevalence of psoriatic arthritis. Subjects will be seen and evaluated by a dermatologist at visit 1 and by a rheumatologist at visit 2. A subset of subjects will then go on to visit 3 for imaging procedures (x-ray, MRI, and ultrasound).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
1,013
1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results
PsA: inflammatory arthritis associated with psoriasis that can have an indolent and progressive course. Percentage of participants with PsA was calculated by dividing the number of participants who were classified as positive by the rheumatologist and the total number of participants evaluated using medical history, physical examination and laboratory results as the basis for the diagnosis.
Time frame: Week 0 through Week 8
Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination and Medical History
PsA: inflammatory arthritis associated with psoriasis that can have an indolent and progressive course. Percentage of participants with PsA was calculated by dividing the number of participants who were classified as positive by the rheumatologist and the total number of participants evaluated using medical history and physical examination as the basis for the diagnosis.
Time frame: Week 0 through Week 8
Percentage of Participants With Undiagnosed Psoriatic Arthritis (PsA)
PsA: inflammatory arthritis associated with psoriasis that can have an indolent and progressive course. Primary PsA diagnosis made by rheumatologist based on physical examination, medical history and laboratory test results. Secondary PsA diagnosis made by rheumatologist based on physical examination and medical history only. For both, numerator was number of participants with "No" answer to question concerning previous diagnosis of PsA at Visit 1 (dermatology visit) and were subsequently classified as positive by rheumatologist; denominator was total number of participants evaluated for PsA.
Time frame: Week 0 through Week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Modern Research Assoc. PLLC
Dallas, Texas, United States
Rheumatology Practive of Scott Zashin, MD
Dallas, Texas, United States
Center for Clinical Studies Ltd LLP
Houston, Texas, United States
Rheumatology Associates of Houston
Houston, Texas, United States
Center for Clinical Studies LTD LLP
Webster, Texas, United States
Dermatology Associates
Seattle, Washington, United States
Universitair Ziekenhuis Gent
Ghent, Belgium, Belgium
Algemeen Ziekenhuis St. Jan
Bruges, Belgium
Kirk Barber Research
Calgary, Alberta, Canada
Stratica Medical
Edmonton, Alberta, Canada
...and 35 more locations